Q-omics provides the consensus-scored TAF9P3 profile across patient tissues and cancer cell-line models. TAF9P3 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TAF9P3 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, TAF9P3 RNA expression shows 18,755 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KIRC, and THYM as cancer lineages where TAF9P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TAF9P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TAF9P3 survival associations across molecular data types. TAF9P3 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TAF9P3 RNA expression–survival associations across cancer types. High TAF9P3 expression shows unfavorable associations in ESCA and ACC, but favorable associations in HNSC, UCS, LAML and COAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TAF9P3 RNA expression.
This table summarizes TAF9P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TAF9P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TAF9P3 shows lower tumor expression in BRCA and BLCA and higher tumor expression in KIRC, KIRP, CHOL and STAD. The KIRC box plot shows higher TAF9P3 RNA expression in tumor versus normal tissue (log2 FC = +0.447, t-test p < 0.001).
This table shows molecular features associated with TAF9P3 in patient tissues and cancer cell lines. In patient samples, TAF9P3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
